Dr. Asha Nayak M.D. Ph.D. is Independent Director of the company. She served as Chief Medical Officer at Intel Corporation, or Intel, from 2012 to 2018, where she guided its healthcare investment strategy and provided clinical and business leadership to Intel’s broad spectrum of healthcare programs. Dr. Nayak served as co-principal investigator on four clinical studies in the areas of oncology, cardiology, and clinical innovation that demonstrated the value of Intel technologies and emerging forms of clinical data. Before joining Intel, from 2010 to 2012 she was Vice President at New Leaf Venture Partners, L.L.C., guiding its investments in the medical device sector. Earlier, from 2002 to 2009, Dr. Nayak created and led several new therapy programs at Medtronic plc and served on its long-term strategic plan and investment committees. Dr. Nayak maintains and has maintained throughout her career an active clinical practice at the Stanford VA emergency department. She is the inventor on numerous patents and is published in several textbooks and peer-reviewed journals. Dr. Nayak received her B.S. from Florida State University, holds an M.D. and Ph.D. in neuroscience from the University of Colorado and completed internal medicine residency and Biodesign Innovation Fellowship programs at Stanford University. Nayak’s qualifications to serve on our Board of Directors include her extensive experience in the development and business strategy of multiple companies in the life sciences sector. Dr. Nayak will resign from the Board of Directors and its committees immediately prior to the Annual Meeting, and we expect that she will continue to serve on the Board of Directors and its committees until such time. Dr. Nayak’s resignation does not arise from any disagreement on any matter relating to the Company’s strategy, operations, policies or practices.
As the Independent Director of Sage Therapeutics Inc, the total compensation of Asha Nayak at Sage Therapeutics Inc is $1,122,300. There are 14 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
Asha Nayak is 49, he's been the Independent Director of Sage Therapeutics Inc since 2017. There are 16 older and no younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
Asha's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen oraz Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
Sage Therapeutics Inc executives and other stock owners filed with the SEC include: